Summit Therapeutics SMMT Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The official record: Summit Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Summit Therapeutics's net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Summit Therapeutics's net change in cash?
- Summit Therapeutics (SMMT) reported net change in cash of -$118.75M in Q1 2026.
- How has Summit Therapeutics's net change in cash changed year-over-year?
- Summit Therapeutics's net change in cash decreased by 211.3% year-over-year, from $106.66M to -$118.75M.
- What is the long-term trend for Summit Therapeutics's net change in cash?
- Over 2 years (2022 to 2024), Summit Therapeutics's net change in cash has grown at a -75.8% compound annual growth rate (CAGR), from $576.82M to $33.76M.
- What does net change in cash mean?
- The total change in the company's cash balance over the period.
- How do you interpret net change in cash?
- A positive value indicates net cash generation, while a negative value indicates cash burn, which is a critical indicator of financial sustainability for pre-revenue companies.
- How does net change in cash compare across companies?
- Standard metric for all public companies; essential for assessing the 'cash runway' of clinical-stage biotechs.